Crescent Capital BDC, Inc. - 10-Q Summary (Period Ended Sept 30, 2016)
Business Context and Reporting Period
Crescent Capital BDC, Inc. is an externally managed, closed-end, non-diversified business development company (BDC) and regulated investment company (RIC). The company invests primarily in secured and unsecured debt and related equity securities of private U.S. middle-market companies. This report covers the quarterly period ended September 30, 2016, and the nine-month period from inception (February 5, 2015) through September 30, 2016.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2016 | Nine Months Ended Sept 30, 2016 | As of Sept 30, 2016 |
|---|---|---|---|
| Total Investment Income | $3,456,059 | $8,869,706 | N/A |
| Net Investment Income (After Tax) | $1,581,872 | $3,792,742 | N/A |
| Net Increase in Net Assets from Operations | $3,204,744 | $7,414,950 | N/A |
| Net Asset Value (NAV) per Share | N/A | N/A | $19.77 |
| Total Investments (Fair Value) | N/A | N/A | $209,159,961 |
| Total Debt (Carrying Value) | N/A | N/A | $93,659,755 |
| Cash and Cash Equivalents | N/A | N/A | $5,878,724 |
| Asset Coverage Ratio | N/A | N/A | 2.25 to 1 |
| Weighted Average Interest Rate (Debt) | 2.59% | 2.34% | N/A |
Material Changes vs. Prior Period
- Portfolio Growth: Total investments at fair value increased from $138.1 million at December 31, 2015, to $209.2 million at September 30, 2016. This growth was driven by capital drawdowns of $38.0 million during the nine-month period.
- Income Expansion: Net investment income for the nine months ended September 30, 2016, was $3.79 million, a significant increase compared to $39,896 for the period from inception to September 30, 2015, reflecting the larger deployed capital base.
- Debt Utilization: Total debt increased from $54.5 million (Dec 31, 2015) to $93.7 million (Sept 30, 2016). The company added a new $75 million SPV Asset Facility in March 2016 and amended its Revolving Credit Facility.
- Unrealized Gains: The portfolio shifted from a net unrealized depreciation of $2.98 million at year-end 2015 to a net unrealized appreciation of $1.04 million at September 30, 2016.
Guidance, Outlook, and Risks
Management Commentary: Management continues to focus on maximizing total return through current income and capital appreciation. The company has successfully deployed capital into a diversified portfolio of 103 portfolio companies. The Advisor has waived management fees in excess of specific thresholds to support the company prior to a qualified IPO.
Capital Resources: As of September 30, 2016, the company had $92.1 million in unfunded capital commitments from investors. Combined with cash on hand and available borrowing capacity ($20.5 million), liquidity is deemed sufficient for foreseeable operations.
Risks and Contingencies:
- Market Risk: Significant exposure to credit quality, interest rate fluctuations, and liquidity constraints inherent in private middle-market debt.
- Valuation Risk: A substantial portion of the portfolio ($82.7 million) is classified as Level 3 (unobservable inputs), requiring fair value determination by the Board.
- Leverage Risk: The company utilizes debt to enhance returns, subject to the 1940 Act asset coverage ratio requirement of 2:1.
- Unfunded Commitments: The company has $6.8 million in unfunded loan commitments as of September 30, 2016.
Investor Verification Checklist
- Capital Drawdowns: Verify the status of the $92.1 million in unfunded capital commitments and the timeline for future funding requirements.
- Level 3 Valuations: Review the specific unobservable inputs (discount rates, EBITDA multiples) used to value the $82.7 million in Level 3 assets.
- Debt Covenants: Confirm continued compliance with the 2:1 asset coverage ratio and other covenants in the Revolving Credit Facility and SPV Asset Facility.
- Portfolio Concentration: Assess the impact of the top holdings (e.g., Synarc - Biocare Holdings at 13.1% of net assets) on overall portfolio risk.
- Fee Waivers: Monitor the duration and conditions of the management fee waivers provided by the Advisor.